GoAI
Get started
PolyPid Ltd. logo

PolyPid Ltd.

PYPD

NASDAQHealthcareBiotechnology

Open in GoAI

Previous close

$5.10

+$0.02 · +0.39%

Aug 21, 4:00 PM ET

PYPD company overview

Regular session · ET · Market data may be delayed.

GoAI snapshot

AI-powered factor overview

Jul 10, 2026

GoAI score

Sell

Trim exposure — unfavorable risk-reward

Valuation

26

Expensive

Momentum

81

Strong Up

Sentiment

42

Mixed

Risk resilience

46

Elevated Risk

Full GoAI research

Thesis, catalysts, evidence, and risk analysis.

View full GoAI research

AI-generated, informational only, and not investment advice.

Company profile

Company website

PolyPid Ltd. is an advanced-stage biopharmaceutical company specializing in the development, manufacturing, and commercialization of therapeutic solutions. These solutions are based on its proprietary polymer-lipid encapsulation matrix (PLEX) platform, with the goal of addressing significant unmet medical needs. The company's leading product candidate, D-PLEX100, is currently undergoing Phase III clinical trials. It is being evaluated for its efficacy in preventing surgical site infections (SSIs) following both sternal (bone) and abdominal (soft tissue) procedures. Established in 2008, PolyPid Ltd. is headquartered in Petah Tikva, Israel.

Industry
Biotechnology
Sector
Healthcare
Headquarters
IL
CEO
Dikla Czaczkes Akselbrad
Listed since
Jun 26, 2020
Employees
72

Market position

Day range

Current $5.10

52-week range

Current $5.10

Open
$5.10
Previous close
$5.08
Volume
169.11K
0.94× average
Average volume
180.32K
Average daily volume
Market cap
97.32M USD
Beta
1.39
Market reference 1
50-day average
$4.7635
+7.06% above average
200-day average
$4.4338
+15.03% above average

Financials

Financial snapshot

Latest / TTM

Valuation & yield

Enterprise value
67.34M USD
P/E (TTM)
-3.45×
P/B (TTM)
21.43×
P/S (TTM)
0×
EV / EBITDA
-2.11×
Earnings yield
-48.16%
Free cash flow yield
0.00%
Dividend yield
0.00%

Profitability & efficiency

Gross margin
0.00%
Operating margin
0.00%
Net margin
0.00%
Return on equity
-311.39%
Return on assets
-153.18%
Return on invested capital
-197.21%

Financial health

Debt / equity
0.29×
Current ratio
1.97×
Altman Z-score
-29.86
Piotroski F-score
1 of 9

Financial statements

Income trends

Operating income

−32.97M USD-17.62%

Net income

−34.17M USD-17.73%
Income trends across reported periods−20.84M USD−28.95M USD−37.06M USD−45.17M USDOperating income, FY2021: −43.15M USDOperating income, FY2022: −38.89M USDOperating income, FY2023: −22.87M USDOperating income, FY2024: −28.03M USDOperating income, FY2025: −32.97M USDNet income, FY2021: −40.71M USDNet income, FY2022: −39.53M USDNet income, FY2023: −23.87M USDNet income, FY2024: −29.02M USDNet income, FY2025: −34.17M USDFY2021FY2022FY2023FY2024FY2025
Operating income FY2021 −43.15M USD. Operating income FY2022 −38.89M USD. Operating income FY2023 −22.87M USD. Operating income FY2024 −28.03M USD. Operating income FY2025 −32.97M USD. Net income FY2021 −40.71M USD. Net income FY2022 −39.53M USD. Net income FY2023 −23.87M USD. Net income FY2024 −29.02M USD. Net income FY2025 −34.17M USD.
Metric (USD)FY2025FY2024FY2023FY2022FY2021
Cost of goods sold———1.72M USD1.12M USD
Gross profit———−1.72M USD−1.12M USD
Research and development23.81M USD22.81M USD16.15M USD27.99M USD30.42M USD
Selling, general, and administrative9.16M USD5.22M USD6.72M USD10.9M USD12.45M USD
Operating expenses32.97M USD28.03M USD22.87M USD37.17M USD42.03M USD
Interest income—442K USD548K USD267K USD468K USD
Interest expense685K USD1.53M USD1.71M USD1.34M USD—
Depreciation and amortization1.62M USD1.62M USD1.82M USD1.72M USD1.12M USD
Operating income−32.97M USD−28.03M USD−22.87M USD−38.89M USD−43.15M USD
Net income−34.17M USD−29.02M USD−23.87M USD−39.53M USD−40.71M USD

Company facts updated Aug 24, 2026.

Earnings

EPS beat rate
55%
6 beats, 5 misses, 0 met estimates
Average EPS surprise
-6.01%
11 comparable reports
Latest EPS result
-0.35
Estimate -0.38 · Beat by 7.28%

EPS: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly EPS actual values compared with estimates-0.29-0.59-0.89-1.19Q1 '25MissQ2 '25BeatQ3 '25MissQ4 '25BeatQ1 '26MissQ2 '26BeatQ3 '26BeatQ4 '26Estimate
Q1 2025, reported Feb 12, 2025: actual -1.13, estimate -0.9, surprise -25.56%, Miss. Q2 2025, reported May 14, 2025: actual -0.7, estimate -0.8, surprise +12.50%, Beat. Q3 2025, reported Aug 13, 2025: actual -0.78, estimate -0.53, surprise -47.17%, Miss. Q4 2025, reported Nov 12, 2025: actual -0.37, estimate -0.54, surprise +31.48%, Beat. Q1 2026, reported Feb 11, 2026: actual -0.41, estimate -0.34, surprise -20.59%, Miss. Q2 2026, reported May 13, 2026: actual -0.35, estimate -0.47, surprise +25.53%, Beat. Q3 2026, reported Aug 12, 2026: actual -0.35, estimate -0.378, surprise +7.28%, Beat. Q4 2026, reported Nov 11, 2026: actual —, estimate -0.378, surprise —, Comparison unavailable.

Revenue: actual versus estimate

Recent quarterly results

ActualEstimate
Quarterly Revenue actual values compared with estimates840K646.67K453.33K260KQ3 '26EstimateQ4 '26Estimate
Q3 2026, reported Aug 12, 2026: actual —, estimate 300K USD, surprise —, Comparison unavailable. Q4 2026, reported Nov 11, 2026: actual —, estimate 800K USD, surprise —, Comparison unavailable.

Analyst ratings

Third-party consensus; not a GoAI recommendation.

Analyst price target

Average target

$12.50

145.10% upside
Past 12 months12-month forecastHigh $13.00Average $12.50Low $12.00

Rating distribution

9 ratings
Strong buy00%
Buy889%
Hold111%
Sell00%
Strong sell00%

Recent analyst actions

5 institutions
Craig-HallummaintainBuy
JMP SecuritiesmaintainMarket Outperform
BarclaysmaintainEqual Weight

Corporate actions

Corporate action history

Stock split

Effective Sep 21, 2023

1:30

PYPD peers

Amgen Inc. logo

AMGN

Amgen Inc.

$439.33

+1.29%

Gilead Sciences, Inc. logo

GILD

Gilead Sciences, Inc.

$146.12

+1.87%

Vertex Pharmaceuticals Incorporated logo

VRTX

Vertex Pharmaceuticals Incorporated

$548.05

+1.44%

Intuitive Surgical, Inc. logo

ISRG

Intuitive Surgical, Inc.

$378.81

+1.16%

Sanofi logo

SNY

Sanofi

$45.85

+1.55%

Regeneron Pharmaceuticals, Inc. logo

REGN

Regeneron Pharmaceuticals, Inc.

$834.04

+0.90%

Continue in GoAI

Research PYPD

research.disclaimer